Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Enzalutamide; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms AQUARiUS
- Sponsors Janssen Pharmaceutica
- 07 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 19 Jan 2018 Planned End Date changed from 21 Mar 2018 to 1 Mar 2018.
- 19 Jan 2018 Planned primary completion date changed from 31 Oct 2017 to 1 Mar 2018.